Sagimet Biosciences Inc. Series A
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell SGMT and other ETFs, options, and stocks.About SGMT
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
CEODavid A. Happel
CEODavid A. Happel
Employees14
Employees14
HeadquartersSan Mateo, California
HeadquartersSan Mateo, California
Founded2006
Founded2006
Employees14
Employees14
SGMT Key Statistics
Market cap208.14M
Market cap208.14M
Price-Earnings ratio-3.57
Price-Earnings ratio-3.57
Dividend yield—
Dividend yield—
Average volume615.39K
Average volume615.39K
High today—
High today—
Low today—
Low today—
Open price$6.43
Open price$6.43
Volume0.00
Volume0.00
52 Week high$11.41
52 Week high$11.41
52 Week low$1.73
52 Week low$1.73
Stock Snapshot
As of today, Sagimet Biosciences Inc. Series A(SGMT) shares are valued at $6.27. The company's market cap stands at 208.14M, with a P/E ratio of -3.57.
During the trading day, Sagimet Biosciences Inc. Series A(SGMT) stock saw an opening price of $6.43, a peak of —, and a bottom of —.
Trading activity shows a volume of 0, compared to an average daily volume of 615.39K.
Over the past 52 weeks, Sagimet Biosciences Inc. Series A(SGMT) stock has traded between a high of $11.41 and a low of $1.73.
Over the past 52 weeks, Sagimet Biosciences Inc. Series A(SGMT) stock has traded between a high of $11.41 and a low of $1.73.
Analyst ratings
100%
of 9 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own SGMT. This list is generated using Robinhood data, and it’s not a recommendation.